




NAPA Research Subcommittee Overview of Scientific Advances, Opportunities, and Challenges

Randall Bateman, M.D.

Charles F. and Joanne Knight Distinguished Professor of Neurology
Washington University School of Medicine



NAPA goal to prevent and effectively treat AD/ADRD: Recent milestones and current landscape



What still needs to be done?

- **Biomarkers (Dr. Lawren Vandevrede)**
 - Better biomarkers for AD/ADRD
 - Expand patient access to clinical care for standard of care diagnosis
 - A precision medicine approach to detect the disease earlier and tailor treatment plans to an individual's unique disease and risk profiles
- **Down Syndrome trials (Dr. Michael Rafii)**
 - Research to answer outstanding questions on current disease-modifying therapies for AD/ADRD
 - Increase knowledge of risk and protective factors in individuals and across diverse populations
- **Prevention (Dr. Reisa Sperling)**
 - Development and testing of additional drug candidates in more representative, efficient, and practical clinical trials
 - Increase knowledge of risk and protective factors in individuals and across diverse populations
 - Expand patient access to clinical care for treatment and *incorporate clinical trials into the care model*
- **Artificial intelligence (Drs. Wendy Nilsen and Randall Bateman)**
 - Leverage artificial intelligence and data to speed discoveries – build predictive models of the aging human brain and identify targets and mechanisms for prevention and treatment


Increased federal research funding and investments are needed to accomplish the above and meet NAPA goals.

3

Why increased funding now?

- Federally funded AD/ADRD research has delivered breakthroughs including blood tests for early detection and the first treatments that slow disease progression
- However, current **spending on research is less than 1% of the annual cost** for Alzheimer's disease, far below other major national issues

Other serious national problems are funded at 3-17% of its cost



4

2026 Research Subcommittee Recommendations

- 1) Increase federal research funding and investments to meet NAPA goals of preventing and treating Alzheimer's disease and related dementias.
- 2) Sustain current trials and fund new long-term prevention and early intervention trials for AD/ADRD.
- 3) In the revised National Plan to Address Alzheimer's Disease, Congress and HHS should **invest in the application of artificial intelligence and big data** to transform discoveries in AD/ADRD mechanisms, diagnosis, treatments, and management.
- 4) Congress and HHS should leverage the revised National Plan to Address Alzheimer's Disease to **establish a coordinated national AD/ADRD clinical research infrastructure**. Modeled on the highly successful National Cancer Institute (NCI) system, this infrastructure will greatly accelerate the development of prevention, diagnosis, monitoring, and treatment approaches and expand patient access to clinical trials nationally.

5